Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.68 |
| ▸ | JAK2 | O60674 | 5/20 | 0.68 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 8/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485401 | 0.94 | JAK3 (0.68) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485384 | 0.91 | JAK2 (0.80) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485387 | 0.87 | JAK2 (0.57) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL3211154 | 0.87 | AXL (0.65) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485388 | 0.85 | JAK2 (0.77) | JAK3JAK2EGFRBRD4CDK2 | |
| SCHEMBL13535840 | 0.83 | JAK3 (0.63) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485385 | 0.82 | JAK2 (0.61) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485399 | 0.82 | EGFR (0.72) | JAK3JAK2EGFRBRD4CDK2 | |
| SCHEMBL13485389 | 0.82 | JAK2 (0.61) | JAK3JAK2AXLEGFRBRD4 | |
| SCHEMBL13485395 | 0.82 | PAK1 (0.55) | JAK3JAK2AXLEGFRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | JAK3 5/4885JAK2 1/4885AXL 53/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885AXL 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.